UTHR biotech catalysts & pipeline

UNITED THERAPEUTICS CORP · Data as of 2026-10-25

Upcoming catalysts

ralinepag DPI — IND submission

2026

We believe that these submissions, accompanied by our planned filings later this year – an IND application for ralinepag DPI and an NDA for treprostinil SMI – may herald an opportunity for a quantum increase in our growth by the end of the decade.

Source filing

treprostinil SMI — NDA/BLA submission

2026

We believe that these submissions, accompanied by our planned filings later this year – an IND application for ralinepag DPI and an NDA for treprostinil SMI – may herald an opportunity for a quantum increase in our growth by the end of the decade.

Source filing

ralinepag — Regulatory decision

2027

By next year, we expect potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH, two potentially transformative, multi-billion-dollar catalysts that could significantly enhance our growth profile.

Source filing

Nebulized Tyvaso (treprostinil) — Regulatory decision

Apr 2027

United Therapeutics anticipates the agency's review to be complete in late April 2027.

Source filing

Explore the free biotech catalyst calendar